Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 351

1.

Extended 5-Year Follow-up Results of a Phase Ib Study (BRIM7) of Vemurafenib and Cobimetinib in BRAF-Mutant Melanoma.

Ribas A, Daud A, Pavlick AC, Gonzalez R, Lewis KD, Hamid O, Gajewski TF, Puzanov I, Wongchenko M, Rooney I, Hsu JJ, Yan Y, Park E, McArthur GA.

Clin Cancer Res. 2019 Nov 15. doi: 10.1158/1078-0432.CCR-18-4180. [Epub ahead of print]

PMID:
31732523
2.

A distinct pre-treatment immune gene signature in lentigo maligna is associated with imiquimod response.

Halse H, Caramia F, McLean CA, Wang M, Aw Yeang HX, Keam SP, Behren A, Ly L, Haskett M, Cebon J, McArthur GA, Neeson PJ, Mar VJ.

J Invest Dermatol. 2019 Sep 30. pii: S0022-202X(19)33294-4. doi: 10.1016/j.jid.2019.07.725. [Epub ahead of print]

PMID:
31580843
3.

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hogg D, Hill A, Márquez-Rodas I, Haanen J, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bastholt L, Rizzo JI, Balogh A, Moshyk A, Hodi FS, Wolchok JD.

N Engl J Med. 2019 Oct 17;381(16):1535-1546. doi: 10.1056/NEJMoa1910836. Epub 2019 Sep 28.

PMID:
31562797
4.

Lymphatic and Hematogenous Dissemination in Patients With Primary Cutaneous Melanoma.

Adler NR, McArthur GA, Mar VJ.

JAMA Dermatol. 2019 Sep 11. doi: 10.1001/jamadermatol.2019.2658. [Epub ahead of print] No abstract available.

PMID:
31509186
5.

High-resolution MRI demonstrates that more than ninety percent of small intracranial melanoma metastases develop in close relationship to the leptomeninges.

Lasocki A, Khoo C, Lau P, Kok DL, McArthur GA.

Neuro Oncol. 2019 Sep 9. pii: noz171. doi: 10.1093/neuonc/noz171. [Epub ahead of print]

PMID:
31498868
6.

Regulation of PRMT5-MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma.

AbuHammad S, Cullinane C, Martin C, Bacolas Z, Ward T, Chen H, Slater A, Ardley K, Kirby L, Chan KT, Brajanovski N, Smith LK, Rao AD, Lelliott EJ, Kleinschmidt M, Vergara IA, Papenfuss AT, Lau P, Ghosh P, Haupt S, Haupt Y, Sanij E, Poortinga G, Pearson RB, Falk H, Curtis DJ, Stupple P, Devlin M, Street I, Davies MA, McArthur GA, Sheppard KE.

Proc Natl Acad Sci U S A. 2019 Sep 3;116(36):17990-18000. doi: 10.1073/pnas.1901323116. Epub 2019 Aug 22.

7.

Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIM.

Lewis KD, Larkin J, Ribas A, Flaherty KT, McArthur GA, Ascierto PA, Dréno B, Yan Y, Wongchenko M, McKenna E, Zhu Q, Mun Y, Hauschild A.

Br J Cancer. 2019 Oct;121(7):522-528. doi: 10.1038/s41416-019-0546-y. Epub 2019 Aug 16.

8.

Acute toxic epidermal necrolysis reaction post single dose pembrolizumab with preceding cephalosporin exposure: successful rechallenge with anti-PD-1 therapy.

Lomax AJ, McQuillan PIA, Hall A, McArthur GA.

Intern Med J. 2019 Aug;49(8):1051-1053. doi: 10.1111/imj.14388. No abstract available.

PMID:
31387152
9.

Re: Jain A, Dunlop R, Hems T, Tang JB. Outcomes of surgical repair of a single digital nerve in adults. J Hand Surg Eur. 2019, 44: 560-5.

McArthur G, Horwitz M, Eckersley R.

J Hand Surg Eur Vol. 2019 Oct;44(8):869-871. doi: 10.1177/1753193419864487. Epub 2019 Jul 24. No abstract available.

PMID:
31337244
10.

The mind minds minds: The effect of intentional stance on the neural encoding of joint attention.

Caruana N, McArthur G.

Cogn Affect Behav Neurosci. 2019 Dec;19(6):1479-1491. doi: 10.3758/s13415-019-00734-y.

PMID:
31243694
11.

Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib.

Lewis K, Hauschild A, Larkin J, Ribas A, Flaherty KT, McArthur GA, Dréno B, McKenna E, Zhu Q, Mun Y, Ascierto PA.

Eur J Cancer. 2019 Jul;116:45-55. doi: 10.1016/j.ejca.2019.05.002. Epub 2019 Jun 4.

PMID:
31173962
12.

First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study.

Khot A, Brajanovski N, Cameron DP, Hein N, Maclachlan KH, Sanij E, Lim J, Soong J, Link E, Blombery P, Thompson ER, Fellowes A, Sheppard KE, McArthur GA, Pearson RB, Hannan RD, Poortinga G, Harrison SJ.

Cancer Discov. 2019 Aug;9(8):1036-1049. doi: 10.1158/2159-8290.CD-18-1455. Epub 2019 May 15.

PMID:
31092402
13.

Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series.

Banks PD, Lasocki A, Lau PKH, Sandhu S, McArthur G, Shackleton M.

Health Sci Rep. 2019 Feb 1;2(3):e115. doi: 10.1002/hsr2.115. eCollection 2019 Mar.

14.

Adverse events 2.0-Let us get SERIOs: New reporting for adverse event outcomes needed in the era of immunooncology.

Heinzerling L, Ascierto PA, Dummer R, Gogas H, Grob JJ, Lebbe C, Long GV, McArthur G, Moslehi JJ, Neilan TG, Ribas A, Robert C, Schadendorf D, Wolchok JD, Hauschild A.

Eur J Cancer. 2019 May;112:29-31. doi: 10.1016/j.ejca.2019.01.015. Epub 2019 Mar 21. No abstract available.

PMID:
30903870
15.

Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.

Tan L, Sandhu S, Lee RJ, Li J, Callahan J, Ftouni S, Dhomen N, Middlehurst P, Wallace A, Raleigh J, Hatzimihalis A, Henderson MA, Shackleton M, Haydon A, Mar V, Gyorki DE, Oudit D, Dawson MA, Hicks RJ, Lorigan P, McArthur GA, Marais R, Wong SQ, Dawson SJ.

Ann Oncol. 2019 May 1;30(5):804-814. doi: 10.1093/annonc/mdz048.

PMID:
30838379
16.

Somatic Hypermutation of the YAP Oncogene in a Human Cutaneous Melanoma.

Zhang X, Tang JZ, Vergara IA, Zhang Y, Szeto P, Yang L, Mintoff C, Colebatch A, McIntosh L, Mitchell KA, Shaw E, Rizos H, Long GV, Hayward N, McArthur GA, Papenfuss AT, Harvey KF, Shackleton M.

Mol Cancer Res. 2019 Jul;17(7):1435-1449. doi: 10.1158/1541-7786.MCR-18-0407. Epub 2019 Mar 4.

PMID:
30833299
17.

Genomic Features of Exceptional Response in Vemurafenib ± Cobimetinib-treated Patients with BRAF V600-mutated Metastatic Melanoma.

Yan Y, Wongchenko MJ, Robert C, Larkin J, Ascierto PA, Dréno B, Maio M, Garbe C, Chapman PB, Sosman JA, Shi Z, Koeppen H, Hsu JJ, Chang I, Caro I, Rooney I, McArthur GA, Ribas A.

Clin Cancer Res. 2019 Jun 1;25(11):3239-3246. doi: 10.1158/1078-0432.CCR-18-0720. Epub 2019 Mar 1.

PMID:
30824584
18.

Molecular Genomic Profiling of Melanocytic Nevi.

Colebatch AJ, Ferguson P, Newell F, Kazakoff SH, Witkowski T, Dobrovic A, Johansson PA, Saw RPM, Stretch JR, McArthur GA, Long GV, Thompson JF, Pearson JV, Mann GJ, Hayward NK, Waddell N, Scolyer RA, Wilmott JS.

J Invest Dermatol. 2019 Aug;139(8):1762-1768. doi: 10.1016/j.jid.2018.12.033. Epub 2019 Feb 14.

PMID:
30772300
19.

Genomic Analysis of Circulating Tumor DNA Using a Melanoma-Specific UltraSEEK Oncogene Panel.

Gray ES, Witkowski T, Pereira M, Calapre L, Herron K, Irwin D, Chapman B, Khattak MA, Raleigh J, Hatzimihalis A, Cebon J, Sandhu S, McArthur GA, Millward M, Ziman M, Dobrovic A, Wong SQ.

J Mol Diagn. 2019 May;21(3):418-426. doi: 10.1016/j.jmoldx.2018.12.001. Epub 2019 Feb 5.

PMID:
30731208
20.

A novel immunogenic mouse model of melanoma for the preclinical assessment of combination targeted and immune-based therapy.

Lelliott EJ, Cullinane C, Martin CA, Walker R, Ramsbottom KM, Souza-Fonseca-Guimaraes F, Abuhammad S, Michie J, Kirby L, Young RJ, Slater A, Lau P, Meeth K, Oliaro J, Haynes N, McArthur GA, Sheppard KE.

Sci Rep. 2019 Feb 4;9(1):1225. doi: 10.1038/s41598-018-37883-y.

21.

Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation.

Diesch J, Bywater MJ, Sanij E, Cameron DP, Schierding W, Brajanovski N, Son J, Sornkom J, Hein N, Evers M, Pearson RB, McArthur GA, Ganley ARD, O'Sullivan JM, Hannan RD, Poortinga G.

Commun Biol. 2019 Jan 28;2:39. doi: 10.1038/s42003-019-0284-y. eCollection 2019.

22.

Hydrogen peroxide in the operating theatre: Too dilute to dilute?

Welman T, McKean AR, Torres-Grau J, Tickunas T, McArthur G.

Injury. 2019 Feb;50(2):369-370. doi: 10.1016/j.injury.2018.12.010. Epub 2018 Dec 5. No abstract available.

PMID:
30563713
23.

Syntactic and non-syntactic sources of interference by music on language processing.

Fiveash A, McArthur G, Thompson WF.

Sci Rep. 2018 Dec 17;8(1):17918. doi: 10.1038/s41598-018-36076-x.

24.

The association between poor reading and internalising problems: A systematic review and meta-analysis.

Francis DA, Caruana N, Hudson JL, McArthur GM.

Clin Psychol Rev. 2019 Feb;67:45-60. doi: 10.1016/j.cpr.2018.09.002. Epub 2018 Sep 15. Review.

PMID:
30528985
25.

Phonics training for English-speaking poor readers.

McArthur G, Sheehan Y, Badcock NA, Francis DA, Wang HC, Kohnen S, Banales E, Anandakumar T, Marinus E, Castles A.

Cochrane Database Syst Rev. 2018 Nov 14;11:CD009115. doi: 10.1002/14651858.CD009115.pub3.

26.

Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series.

Mitchell EL, Lau PKH, Khoo C, Liew D, Leung J, Liu B, Rischin A, Frauman AG, Kee D, Smith K, Brady B, Rischin D, Gibson A, Mileshkin L, Klein O, Weickhardt A, Arulananda S, Shackleton M, McArthur G, Östör A, Cebon J, Solomon B, Buchanan RR, Wicks IP, Lo S, Hicks RJ, Sandhu S.

Eur J Cancer. 2018 Dec;105:88-102. doi: 10.1016/j.ejca.2018.09.027. Epub 2018 Nov 13.

PMID:
30439628
27.

Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries.

Kandolf Sekulovic L, Guo J, Agarwala S, Hauschild A, McArthur G, Cinat G, Wainstein A, Caglevic C, Lorigan P, Gogas H, Alvarez M, Duncombe R, Lebbe C, Peris K, Rutkowski P, Stratigos A, Forsea AM, De La Cruz Merino L, Kukushkina M, Dummer R, Hoeller C, Gorry C, Bastholt L, Herceg D, Neyns B, Vieira R, Arenberger P, Bylaite-Bucinskiene M, Babovic N, Banjin M, Putnik K, Todorovic V, Kirov K, Ocvirk J, Zhukavets A, Ymeri A, Stojkovski I, Garbe C.

Eur J Cancer. 2018 Nov;104:201-209. doi: 10.1016/j.ejca.2018.09.013. Epub 2018 Oct 31.

PMID:
30388700
28.

New Era in the Management of Melanoma Brain Metastases.

Tawbi HA, Boutros C, Kok D, Robert C, McArthur G.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:741-750. doi: 10.1200/EDBK_200819. Review.

29.

Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation - Authors' reply.

Long GV, Atkinson V, Hong A, McArthur GA, Menzies AM.

Lancet Oncol. 2018 Aug;19(8):e367. doi: 10.1016/S1470-2045(18)30508-4. No abstract available.

PMID:
30102217
30.

Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.

Hauschild A, Larkin J, Ribas A, Dréno B, Flaherty KT, Ascierto PA, Lewis KD, McKenna E, Zhu Q, Mun Y, McArthur GA.

JAMA Oncol. 2018 Oct 1;4(10):1382-1388. doi: 10.1001/jamaoncol.2018.2668.

31.

Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma.

Halse H, Colebatch AJ, Petrone P, Henderson MA, Mills JK, Snow H, Westwood JA, Sandhu S, Raleigh JM, Behren A, Cebon J, Darcy PK, Kershaw MH, McArthur GA, Gyorki DE, Neeson PJ.

Sci Rep. 2018 Jul 24;8(1):11158. doi: 10.1038/s41598-018-28944-3.

32.

A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors.

Wood PJ, Strong R, McArthur GA, Michael M, Algar E, Muscat A, Rigby L, Ferguson M, Ashley DM.

Cancer Chemother Pharmacol. 2018 Sep;82(3):493-503. doi: 10.1007/s00280-018-3634-4. Epub 2018 Jul 9.

PMID:
29987369
33.

Variations within a subtype: Developmental surface dyslexias in English.

Kohnen S, Nickels L, Geigis L, Coltheart M, McArthur G, Castles A.

Cortex. 2018 Sep;106:151-163. doi: 10.1016/j.cortex.2018.04.008. Epub 2018 May 10.

PMID:
29940400
34.

Language Skills, but Not Frequency Discrimination, Predict Reading Skills in Children at Risk of Dyslexia.

Snowling MJ, Gooch D, McArthur G, Hulme C.

Psychol Sci. 2018 Aug;29(8):1270-1282. doi: 10.1177/0956797618763090. Epub 2018 May 23.

35.

Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy.

Adler NR, Wolfe R, McArthur GA, Kelly JW, Haydon A, McLean CA, Mar VJ.

Br J Cancer. 2018 May;118(10):1289-1295. doi: 10.1038/s41416-018-0088-8. Epub 2018 May 14.

36.

Syntactic processing in music and language: Effects of interrupting auditory streams with alternating timbres.

Fiveash A, Thompson WF, Badcock NA, McArthur G.

Int J Psychophysiol. 2018 Jul;129:31-40. doi: 10.1016/j.ijpsycho.2018.05.003. Epub 2018 May 8.

PMID:
29750978
37.

Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma.

Lewin J, Sayers L, Kee D, Walpole I, Sanelli A, Te Marvelde L, Herschtal A, Spillane J, Gyorki D, Speakman D, Estall V, Donahoe S, Pohl M, Pope K, Chua M, Sandhu S, McArthur GA, McCormack CJ, Henderson M, Hicks RJ, Shackleton M.

Ann Oncol. 2018 Jul 1;29(7):1569-1574. doi: 10.1093/annonc/mdy124.

PMID:
29659679
38.

Oncogenic Signaling Pathways in The Cancer Genome Atlas.

Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M; Cancer Genome Atlas Research Network, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N.

Cell. 2018 Apr 5;173(2):321-337.e10. doi: 10.1016/j.cell.2018.03.035.

39.

Exploring the feasibility and utility of exome-scale tumour sequencing in a clinical setting.

Lee B, Tran B, Hsu AL, Taylor GR, Fox SB, Fellowes A, Marquis R, Mooi J, Desai J, Doig K, Ekert P, Gaff C, Herath D, Hamilton A, James P, Roberts A, Snyder R, Waring P, McArthur G.

Intern Med J. 2018 Jul;48(7):786-794. doi: 10.1111/imj.13806.

PMID:
29607586
40.

Concordance of somatic mutational profile in multiple primary melanomas.

Adler NR, McLean CA, Wolfe R, Kelly JW, McArthur GA, Haydon A, Tra T, Cummings N, Mar VJ.

Pigment Cell Melanoma Res. 2018 Sep;31(5):592-603. doi: 10.1111/pcmr.12702. Epub 2018 Apr 15.

PMID:
29603877
41.

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.

Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, Menzies AM, McArthur GA.

Lancet Oncol. 2018 May;19(5):672-681. doi: 10.1016/S1470-2045(18)30139-6. Epub 2018 Mar 27.

PMID:
29602646
42.

Corrigendum to "Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124].

Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Giacomo AD, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P.

Eur J Cancer. 2018 Apr;93:158. doi: 10.1016/j.ejca.2018.02.001. Epub 2018 Mar 13. No abstract available.

PMID:
29548533
43.

No meditation-related changes in the auditory N1 during first-time meditation.

Barnes LJ, McArthur GM, Biedermann BA, de Lissa P, Polito V, Badcock NA.

Int J Psychophysiol. 2018 May;127:26-37. doi: 10.1016/j.ijpsycho.2018.03.003. Epub 2018 Mar 6.

PMID:
29522779
44.

Hand Therapist Led Follow-up for Paediatric Hand Trauma - a Retrospective Study of 139 Closed Hand Injuries.

Plonczak AM, McArthur GJ, Goldsmith N, Horwitz M.

Ortop Traumatol Rehabil. 2017 Dec 30;19(6):531-536. doi: 10.5604/01.3001.0010.8044.

PMID:
29493526
45.

Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma.

Dréno B, Ascierto PA, Atkinson V, Liszkay G, Maio M, Mandalà M, Demidov L, Stroyakovskiy D, Thomas L, de la Cruz-Merino L, Dutriaux C, Garbe C, Bartley K, Karagiannis T, Chang I, Rooney I, Koralek DO, Larkin J, McArthur GA, Ribas A.

Br J Cancer. 2018 Mar 20;118(6):777-784. doi: 10.1038/bjc.2017.488. Epub 2018 Feb 13.

46.

Optimizing Amplification of the GC-Rich TERT Promoter Region Using 7-Deaza-dGTP for Droplet Digital PCR Quantification of TERT Promoter Mutations.

Colebatch AJ, Witkowski T, Waring PM, McArthur GA, Wong SQ, Dobrovic A.

Clin Chem. 2018 Apr;64(4):745-747. doi: 10.1373/clinchem.2017.284257. Epub 2018 Jan 30. No abstract available.

47.

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.

Valpione S, Carlino MS, Mangana J, Mooradian MJ, McArthur G, Schadendorf D, Hauschild A, Menzies AM, Arance A, Ascierto PA, Di Giacomo A, de Rosa F, Larkin J, Park JJ, Goldinger SM, Sullivan RJ, Xu W, Livingstone E, Weichenthal M, Rai R, Gaba L, Long GV, Lorigan P.

Eur J Cancer. 2018 Mar;91:116-124. doi: 10.1016/j.ejca.2017.12.007. Epub 2018 Jan 19. Erratum in: Eur J Cancer. 2018 Mar 13;:.

48.

Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance.

Martin CA, Cullinane C, Kirby L, Abuhammad S, Lelliott EJ, Waldeck K, Young RJ, Brajanovski N, Cameron DP, Walker R, Sanij E, Poortinga G, Hannan RD, Pearson RB, Hicks RJ, McArthur GA, Sheppard KE.

Int J Cancer. 2018 May 15;142(10):2139-2152. doi: 10.1002/ijc.31220. Epub 2018 Jan 3.

49.

Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.

Wongchenko MJ, Ribas A, Dréno B, Ascierto PA, McArthur GA, Gallo JD, Rooney IA, Hsu J, Koeppen H, Yan Y, Larkin J.

Pigment Cell Melanoma Res. 2018 Jul;31(4):516-522. doi: 10.1111/pcmr.12670. Epub 2017 Dec 10.

PMID:
29156488
50.

Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab.

Mohr P, Ascierto P, Arance A, McArthur G, Hernaez A, Kaskel P, Shinde R, Stevinson K.

J Eur Acad Dermatol Venereol. 2018 Jun;32(6):962-971. doi: 10.1111/jdv.14633. Epub 2017 Nov 8.

PMID:
29044660

Supplemental Content

Loading ...
Support Center